524 related articles for article (PubMed ID: 17394637)
21. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
[TBL] [Abstract][Full Text] [Related]
22. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.
Bedwell DM; Kaenjak A; Benos DJ; Bebok Z; Bubien JK; Hong J; Tousson A; Clancy JP; Sorscher EJ
Nat Med; 1997 Nov; 3(11):1280-4. PubMed ID: 9359706
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
[TBL] [Abstract][Full Text] [Related]
25. High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations.
Liang F; Shang H; Jordan NJ; Wong E; Mercadante D; Saltz J; Mahiou J; Bihler HJ; Mense M
SLAS Technol; 2017 Jun; 22(3):315-324. PubMed ID: 28376702
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
27. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
[TBL] [Abstract][Full Text] [Related]
29. Mutation specific therapy in CF.
Kerem E
Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
[TBL] [Abstract][Full Text] [Related]
30. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans.
Stanke F; Ballmann M; Bronsveld I; Dörk T; Gallati S; Laabs U; Derichs N; Ritzka M; Posselt HG; Harms HK; Griese M; Blau H; Mastella G; Bijman J; Veeze H; Tümmler B
J Med Genet; 2008 Jan; 45(1):47-54. PubMed ID: 18178635
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
[TBL] [Abstract][Full Text] [Related]
32. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
De Stefano D; Villella VR; Esposito S; Tosco A; Sepe A; De Gregorio F; Salvadori L; Grassia R; Leone CA; De Rosa G; Maiuri MC; Pettoello-Mantovani M; Guido S; Bossi A; Zolin A; Venerando A; Pinna LA; Mehta A; Bona G; Kroemer G; Maiuri L; Raia V
Autophagy; 2014; 10(11):2053-74. PubMed ID: 25350163
[TBL] [Abstract][Full Text] [Related]
33. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport.
Sermet-Gaudelus I; Girodon E; Sands D; Stremmler N; Vavrova V; Deneuville E; Reix P; Bui S; Huet F; Lebourgeois M; Munck A; Iron A; Skalicka V; Bienvenu T; Roussel D; Lenoir G; Bellon G; Sarles J; Macek M; Roussey M; Fajac I; Edelman A
Am J Respir Crit Care Med; 2010 Oct; 182(7):929-36. PubMed ID: 20538955
[TBL] [Abstract][Full Text] [Related]
34. Variant cystic fibrosis phenotypes in the absence of CFTR mutations.
Groman JD; Meyer ME; Wilmott RW; Zeitlin PL; Cutting GR
N Engl J Med; 2002 Aug; 347(6):401-7. PubMed ID: 12167682
[TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
[TBL] [Abstract][Full Text] [Related]
36. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
Rubenstein RC; Zeitlin PL
Am J Respir Crit Care Med; 1998 Feb; 157(2):484-90. PubMed ID: 9476862
[TBL] [Abstract][Full Text] [Related]
37. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502
[TBL] [Abstract][Full Text] [Related]
38. Induction of a cAMP-stimulated chloride secretion in regenerating poorly differentiated airway epithelial cells by adenovirus-mediated CFTR gene transfer.
Dupuit F; Chinet T; Zahm JM; Pierrot D; Hinnrasky J; Kaplan H; Bonnet N; Puchelle E
Hum Gene Ther; 1997 Aug; 8(12):1439-50. PubMed ID: 9287144
[TBL] [Abstract][Full Text] [Related]
39. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
[TBL] [Abstract][Full Text] [Related]
40. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
